Blog
US Stock IPO | New filings for overseas securities issuance and listing of 3 domestic enterprises including Soft Cloud Technology in US stocks and 4 domestic enterprises in Hong Kong stocks (as of Aug

On August 11, the China Securities Regulatory Commission (CSRC) updated the record-filing status of domestic enterprises issuing securities and listing overseas (initial public offerings and full circulation) (as of August 10, 2023), with a total of 94 domestic enterprises filing records (excluding those that have completed the process). Among them, 67 enterprises plan to file records for listing in Hong Kong, and 27 plan to file records for listing in the United States.
From July 28 to August 10, 7 new enterprises filed records, including 4 for Hong Kong stocks and 3 for US stocks. The 7 enterprises are as follows (blue font indicates US stocks): Guangdong Yijiankang, Yinlong Water, Lalamove, Cloud Tax (Hunan) Technology, Siterra Environmental Protection, Soft Cloud Technology, and Urban Construction Group.

Meanwhile, the International Department issued supplementary material requirements to a total of 11 enterprises, including 2 US stock enterprises (blue font below), as follows:
1.慧算账Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding the variable interest entity (VIE) structure, please explain:
(1) List the status of your company's domestic (including institutional and individual) shareholders' fulfillment of foreign exchange management, overseas investment supervision procedures, etc.;
(2) The consideration and pricing basis for the equity transfer of Dalian WOFE and Qingdao WOFE, the source of funds, the status of tax declaration in accordance with the law, and whether they comply with relevant regulations on overseas investors' mergers and acquisitions of domestic enterprises;
(3) Specific transaction arrangements between relevant parties under the VIE structure, including but not limited to the time, amount, channel and method of financial support for domestic entities, relevant fund flows, profit transfer arrangements, etc.;
(4) The reasons for adjusting the VIE arrangements, and the current operating status of Huizhang Accounting (Beijing).
2. Regarding your company's equity structure, please explain:
(1) The similarities and differences between your company's common shares and each round of preferred shares;
(2) The tax payment status involved in the equity transfer of your company's shareholder Hexie Jinfeng Holdings Limited;
(3) The reasons why your company's management transferred direct shareholdings to the shareholding platform HSZ Management Holding Limited, and explain the establishment time, type and operation mode of the underlying trust, term, rights and obligations of each party, and trust beneficiaries, etc.;
(4) The reasons for establishing the regional partner platform HSZ Alliance Holding Limited, personnel composition, reasons for shareholding, price, pricing basis, source of funds, and whether there is any improper transfer of benefits.
3. Regarding the employee stock ownership plan, please explain the specific platform for employee stock ownership, personnel composition, exercise price, standardized operation status, whether there are external personnel, whether reserved equity is set up, etc.
4. Please explain the data scale of user information collected and stored in your company's domestic operations and sales activities, and whether it meets the requirements of relevant laws and regulations.
2. Lianlian DigitalPlease ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding your company's equity structure and changes, please explain:
(1) The status of tax payment for each equity transfer of your company's shareholders:
(2) The reasons why Xie Jia holds your company's shares on behalf of QING HUANG directly, and whether QING HUANG has any circumstances prohibited by relevant laws and regulations from holding shares directly or indirectly.
2. Regarding your company's employee stock ownership plan, please explain:
(1) Whether there are any unallocated shares in the employee shareholding platforms Xingzhu Investment, Nuoheng Investment and Yousong Investment, other than the shares that have been clearly granted to relevant employees in the filing materials;
(2) The rationality of Xie Jia's investment through your company's employee shareholding platform.
3. Please provide the regulatory opinions from your company's industry regulatory authority.
4. Please explain the scale of user information collected and stored in your company's domestic operations and sales activities, data collection and usage status, whether there are any circumstances of providing information content to third parties, and the arrangements or measures for personal information protection and data security before and after listing.
5. Please explain whether there are any related party relationships and compliance issues between your company's shareholders, directors, supervisors, senior management and the intermediary institutions for this issuance and listing, whether there is any improper transfer of benefits or conflicts of interest, and how the relevant intermediary institutions ensure the independence of their practice.
3. WuXi Biologics (Shanghai) Co., Ltd. (WuXi Biologics)
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Please explain the relevant situation of your company's current issuance and listing plan, including the number of shares issued, the proportion of the total shares after issuance, the estimated amount of funds raised, the issuance method and issuance objects, etc.
2. Regarding the use of funds raised from your company's current issuance and listing, please explain:
(1) Whether the domestic fund-invested projects comply with national industrial policies, and whether there are any necessary approval, verification or filing procedures that have not been completed;
(2) Whether the construction of production facilities in Singapore and the pursuit of strategic alliance, investment and acquisition opportunities involve overseas investment; if so, whether the overseas investment complies with relevant regulations.
3. Regarding your company's option incentive plan, please explain:
(1) The basic information of current incentive recipients, including but not limited to the positions of incentive recipients, the number of shares corresponding to the options granted, and the specific situation of reserved equity;
(2) If incentive recipients hold shares through a trust, please explain the establishment time, type and operation mode of the trust, term, rights and obligations of each trust party, and trust beneficiaries, etc.
4. Regarding your company's domestic assets and their acquisition, please explain:
(1) The status of WXB Investments' fulfillment of relevant regulatory procedures such as foreign investment and foreign exchange management when establishing WuXi Biologics (Wuxi) Co., Ltd.;
(2) The tax payment status (if any) of your company's three transactions: obtaining 100% equity of WuXi Biologics (Wuxi) Co., Ltd. from WXB Investments, and your company's domestic operating entities WuXi Biologics (Shanghai) Co., Ltd. and Changzhou WuXi AppTec Co., Ltd. acquiring the偶联业务 and toxin molecule and linker business assets from Shanghai WuXi Biologics Co., Ltd. and Changzhou AppTec Pharmaceutical Co., Ltd. respectively;
(3) Whether the acquisitions of偶联业务 and toxin molecule and linker business assets by WuXi Biologics (Shanghai) Co., Ltd. and Changzhou WuXi AppTec Co., Ltd. from Shanghai WuXi Biologics Co., Ltd. and Changzhou AppTec Pharmaceutical Co., Ltd. respectively constitute a business combination under the same control in accordance with the principle of substance over form;
(4) The rationality of the large goodwill formed by Changzhou WuXi AppTec Co., Ltd.'s acquisition of toxin molecule and linker business assets from Changzhou AppTec Pharmaceutical Co., Ltd., and whether there is any improper transfer of benefits.
4. Besmile
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding the VIE structure, please explain the reasons for the inconsistency in shareholders and shareholding ratios between the issuer's shareholders and the main domestic operating entity Shenzhen Besmile Precision Instrument Co., Ltd., whether the relevant arrangements may lead to unstable control, risks that may arise from relevant parties' default, and relevant response measures.
2. Please verify the reasons for shareholding, personnel background, price fairness, fulfillment of decision-making procedures, and standardized operation status of your company's direct shareholder Bo Lv Da Ma Si Holding Co., Limited, indirect shareholder Dixiu Holding Co., Limited, and the shareholders of the domestic operating entity Shenzhen Besmile Precision Instrument Co., Ltd. — Shenzhen Beshengzhenghe Investment Consulting Enterprise (Limited Partnership) and Shenzhen Guanzhihe Investment Consulting Enterprise (Limited Partnership), explain whether the relevant parties are domestic and foreign employee shareholding platforms, whether the domestic partnership is a private equity fund, and issue clear conclusionary opinions on whether there is equity holding on behalf of others, improper transfer of benefits, etc.
3. Regarding standardized operation, please explain:
(1) The status of products such as websites, apps, mini-programs developed and operated by the company, the scale of user information collected and stored, data collection and usage status, whether it involves providing personal user information to third parties, and the arrangements or measures for personal information protection and data security before and after listing;
(2) The company has engaged in the act of producing medical device products without obtaining valid qualification licenses, please explain the rectification measures, whether the relevant acts constitute major illegal violations, and whether they constitute a major adverse impact on this issuance and listing in combination with the proportion of relevant product revenue, etc.
5. Baiwang Co., Ltd.
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Please explain the reasons for the inconsistency between the equity transfer price in February 2021 and the prices of the two adjacent equity transfers before and after, and explain the pricing basis and rationality.
2. Please explain the foreign shareholding ratio after the completion of this issuance and "full circulation", and explain the measures and feasibility taken to continuously comply with foreign investment access policies.
3. Please explain the reasons and rationality for establishing two layers of a total of 8 employee shareholding platforms.
4. Please explain the status of products such as websites, apps, mini-programs developed and operated, the scale of user information collected and stored, data collection and usage status, whether there are any circumstances of providing information to third parties, and the arrangements or measures for personal information protection and data security before and after listing.
6. Bojiang Holdings
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding the equity structure, please explain:
(1) The reasons for Bojiang Group introducing Li Rujun, the consideration and payment status of Li Rujun's purchase and sale of Bojiang Group's equity, and tax payment status;
(2) The consideration and payment status of Hangzhou Hanrui's two acquisitions of Bojiang Group's equity, and tax payment status;
(3) The reasons for introducing eight Lishui partnerships, whether the relevant parties are private equity funds, and whether they have fulfilled private equity fund regulatory procedures;
(4) The paid-in status of Bojiang Group's registered capital, and the compliance of Bojiang Group's registered capital not being fully paid and its impact on the company's operation and solvency.
2. Regarding your company's business operations, please explain the specific situation of Bojiang Group, Shanghai Bojiang itself and its operations through subordinate entities, the proportion of relevant business scale, whether a firewall system between proprietary investment business and entrusted management business and a conflict of interest prevention mechanism have been established, and whether they can effectively ensure the independent operation of private equity fund property and the institution's own property.
3. Regarding your company's use of raised funds, please explain whether the company's plan to use 67.5% of the raised funds from this issuance and listing for existing and new fund investments may lead to the public offering of private equity funds.
4. Please explain the rectification and implementation status of regulatory measures implemented by relevant regulatory authorities on your company in the past three years.
7. Meiziran
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding the equity structure, please explain:
(1) The compliance of the establishment of the equity control structure, including but not limited to the specific situation of relevant domestic natural persons and foreign-invested enterprises involved in the establishment and round-trip investment fulfilling regulatory procedures such as foreign exchange management, overseas investment, and foreign investment;
(2) The status of consideration payment, pricing basis and tax declaration and payment in accordance with the law for Anhui Meiziran Environmental Protection Technology Development Co., Ltd.'s acquisition of Zhou Qiyin and Jinzhai Meijia Partnership's equity.
2. Regarding shareholder information, please explain the basic information of your company's shareholders with more than 5% of shares traced down to natural persons, including but not limited to name, nationality, whether they have permanent overseas residence, address, etc.
3. Regarding raised funds, please explain the reasons for the inconsistency between the content disclosed in your company's prospectus and the content in the submitted filing materials. If the use of raised funds involves domestic investment projects, please explain the fulfillment of relevant regulatory procedures.
4. Please explain the rationality of your company's cash dividend in 2023, whether it has a major impact on the company's solvency and sustainable operating capacity, and the necessity and rationality of implementing this issuance and listing and financing in the case of large cash dividends.
8. Yidayun
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding the equity structure, please explain:
(1) The fulfillment of foreign investment procedures when EDA Cloud Company Limited and Global Logistics Services Limited were established, the consideration, pricing basis and tax payment status of each acquisition of Shenzhen Yidayun's equity, etc.;
(2) The fulfillment of foreign exchange registration procedures for natural person shareholders who hold your company's equity through overseas shareholding platforms;
(3) The pricing basis for the new shareholders' investment in the most recent year, and the status of tax declaration and payment in accordance with the law for equity transfers.
2. Regarding equity incentives, please explain the scope and proportion of incentive recipients in the plan before listing, and if there are external personnel, please conduct verification in accordance with the requirements of "Regulatory Guidelines for Overseas Issuance and Listing Category No. 2".
3. Regarding standardized operation, please explain:
(1) Please provide clear basis for whether your company's domestic operating entity's business involves value-added telecommunications business and complies with the "Special Administrative Measures for Foreign Investment Access (Negative List) (2021 Edition)";
(2) The scale of customer information collected and stored by the company's developed and operated websites, apps, mini-programs, etc., data collection and usage status, whether it involves providing personal user information to third parties, and the arrangements or measures for personal information protection and data security before and after listing;
(3) The compliance of your company's domestic operating entity Shenzhen Yidayun Technology Co., Ltd.'s overseas investment, including but not limited to the fulfillment of regulatory procedures such as foreign exchange management and overseas investment, etc.
9. Huhut Technology
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. The compliance of your company's acquisition of assets and equity from domestic enterprises, whether relevant regulatory procedures have been fulfilled in accordance with laws and regulations, and if not, whether it constitutes a substantial obstacle to this issuance.
2. The compliance of your company's equity incentive plan, including but not limited to the background of the establishment of the shareholding plan, specific personnel composition, price fairness, the provisions of the employee shareholding plan's articles of association or agreement, fulfillment of decision-making procedures, standardized operation status, fulfillment of domestic regulatory procedures such as foreign exchange management, the situation of incentivizing external personnel, whether it involves improper transfer of benefits, etc.
10. RoboSense
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding the equity structure, please explain the compliance of your company's equity structure establishment, including but not limited to the fulfillment of regulatory procedures such as foreign exchange management and overseas investment involved in the establishment and round-trip merger and acquisition, tax payment in accordance with the law, etc., and list the capital flows involved in the establishment and round-trip merger and acquisition, and the pricing basis and fairness of equity transfer during the round-trip merger and acquisition.
2. Regarding shareholders and equity changes, please explain:
(1) The legality and compliance of the equity incentive plan, and the scope of recipients of reserved equity, whether there are external personnel and recipients who have not been clearly identified;
(2) Your company's major shareholders hold shares through trusts, please supplement the trust's establishment time, type and operation mode, term, rights and obligations of the parties and beneficiaries, etc.;
(3) The reasons why the price of capital increase on October 27, 2022 and subsequent times increased significantly compared with the price of capital increase on October 21, 2022.
11. Insilico Medicine
Please ask your company to supplement the following matters, and request a lawyer to conduct verification and issue a clear legal opinion:
1. Regarding equity changes:
(1) The status of domestic regulatory procedures such as foreign exchange management, overseas investment, and tax payment fulfilled by domestic shareholders when investing in the issuer;
(2) The reasons and compliance of the domestic operating entity's registered capital not being fully paid or not fully paid, whether it constitutes a substantial impact on this issuance and listing.
2. Regarding the employee incentive plan: Please issue a clear conclusionary opinion on whether the implementation of the employee shareholding plan is in accordance with laws and regulations in accordance with relevant regulations such as the "Trial Measures for the Administration of Domestic Enterprises' Overseas Issuance and Listing of Securities" and supporting guidelines, including but not limited to whether there are unclarified recipients in the equity incentive plan, and if so, please explain whether there is an improper risk of benefit transfer and risk prevention measures.
3. Regarding data security: The situation of the issuer's main domestic operating entity collecting and using medical data, treatment records and other personal information, and the security measures for data before and after listing.

Disclaimer: Some information in this article comes from the internet, and the content released by this official account is for sharing purposes only. If there are any issues involving content and copyright, please contact us. We will handle it as soon as possible.

Jinhe Enterprise Management Group is a global financial consulting and one-stop full-process listing counseling institution, providing domestic and foreign enterprises with rapid growth services from 1 to 10000, guiding enterprises to go public quickly and continuously enhance their capital value to gain global market competitiveness.
Jinhe Enterprise Management Group specializes in researching how business owners should operate correctly and increase capital value in the era of Internet+, capital+, and continuous upgrading of competition, providing entrepreneurs and business owners who hope to go public and achieve continuous value growth with 1-3 years of strategic restructuring, capital operation, investment and financing, business planning, investment promotion and expansion, management consulting and a full set of solutions for going public quickly. It is also a promoter of new business models under the concept of common prosperity, and its concepts and systems are at the leading level in the global marketing field.
The company's overseas headquarters cover countries and regions including the United States, Canada, the United Kingdom, Sweden, the Middle East, Malaysia, Singapore; its China headquarters is located in Lujiazui, Shanghai, with offices in Shenzhen, Hainan and Chengdu. Shanghai Jinhe Enterprise Management Consulting Group, Zhongjin Tianxia (Hainan Province) Investment Co., Ltd., Shanghai Mianmian Equity Investment Fund Management Co., Ltd., Shanghai Brand Development Fund, Shanghai Shijie Enterprise Management Group Co., Ltd., Jinhe (Shanghai) Industrial Co., Ltd. and others form its business matrix, and it has in-depth cooperative relations with many internationally renowned investment banks, funds, accounting firms and law firms.

Contact Us
Contact Us
Consultation Phone:13052224666 (WeChat same number) Ms. Jin
BP Submission:[email protected]
Official Website:https://www.jinhevip.com
Company Address: Jinhe Group, 22nd Floor, China Financial Information Center, No. 18 Dongyuan Road, Pudong New Area, Shanghai

Originally published on 金盒企业管理集团




